Stewart Mitchell is Executive Vice President and Site Head at Sterling’s Deeside facility, and is responsible for leading the company’s bioconjugation and ADC services. His main focus is to grow capacity and capabilities within this area of the business, as well as integrate Sterling’s high potency API offering within its ADC services.
With more than 25 years of industry experience, Mr. Mitchell previously managed sites in the U.K. and U.S. for companies including Rhodia, Shasun, Piramal and ThermoFisher. He joined Sterling in 2021 from CMAC, University of Strathclyde, where he managed multiple technology industrial collaborative projects within advanced pharmaceutical research, manufacturing and training.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.